lyophilised powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
The resulting class of drugs for lowering blood sugar came to be known as the sulfonylureas, starting with Orinase and still in use today in other forms. Unfortunately for diabetics dependent on insulin as a treatment for their condition, this research at Montpellier occurred in the early 1940s and was significantly disrupted by the German occupation of France during World War II. Development of these compounds was taken over by German pharmaceutical companies, which were obviously disinclined to share their bounty with nations upon which they were waging war. The German research was, in turn, disrupted by Germany's defeat in 1945 and the partition of Germany into East and West Germany. The sulfonylureas were trapped in East Germany. In 1952, someone smuggled a sample to a West German pharmaceutical company and research resumed. Clinical trials in diabetics began in 1954 in Berlin. In 1956, two different sulfonylureas were brought to market in Germany under the trade names Nadisan and Rastinon. American pharmaceutical companies in the postwar period had been seeking to establish business relations with the remnants of German pharmaceutical giants weakened by the war and partition of Germany. Upjohn (based in Kalamazoo until its purchase by Pharmacia in the 1990s) made deals with Hoechst, maker of Rastinon. The result was a cross-licensing agreement which produced Orinase. Upjohn stood to open up a whole new arena of treatment for diabetes, one with a built-in and sustainable market, i.e. patient population.
==== Marsupials ==== Order Didelphimorphia Family Didelphidae (opossums) Monodelphis domestica, gray short-tailed opossum (2007) Order Dasyuromorphia Family Dasyuridae Antechinus stuartii, brown antechinus (2020) Sarcophilus harrisii, Tasmanian devil () Sminthopsis crassicaudata, fat-tailed dunnart (ongoing) Dasyurus hallucatus, northern quoll (ongoing) Family Myrmecobiidae Myrmecobius fasciatus, numbat (ongoing) † Family Thylacinidae † Thylacinus cynocephalus, thylacine () Order Peramelemorphia Family Peramelidae Perameles gunnii, eastern barred bandicoot (ongoing) Family Thylacomyidae Macrotis lagotis, greater bilby (ongoing) Order Notoryctemorphia, Family Notoryctidae Notoryctes typhlops, southern marsupial mole (ongoing) Order Diprotodontia Family Macropodidae Macropus eugenii, tammar wallaby (2011) Petrogale penicillata, brush-tailed rock-wallaby (ongoing) Family Potoroidae Bettongia gaimardi, eastern bettong (ongoing) Bettongia penicillata ogilbyi, woylie (2021) Family Petauridae Gymnobelideus leadbeateri, Leadbeater's possum (ongoing) Family Burramyidae Burramys parvus, mountain pygmy possum (ongoing) Family Vombatidae Vombatus ursinus, common wombat (ongoing) Family Phascolarctidae Phascolarctos cinereus, koala (2013 draft)
A white blood cell differential is a medical laboratory test that provides information about the types and amounts of white blood cells in a person's blood. The test, which is usually ordered as part of a complete blood count (CBC), measures the amounts of the five normal white blood cell types – neutrophils, lymphocytes, monocytes, eosinophils and basophils – as well as abnormal cell types if they are present. These results are reported as percentages and absolute values, and compared against reference ranges to determine whether the values are normal, low, or high. Changes in the amounts of white blood cells can aid in the diagnosis of many health conditions, including viral, bacterial, and parasitic infections and blood disorders such as leukaemia. White blood cell differentials may be performed by an automated analyzer – a machine designed to run laboratory tests – or manually, by examining blood smears under a microscope. The test was performed manually until white blood cell differential analyzers were introduced in the 1970s, making the automated differential possible. In the automated differential, a blood sample is loaded onto an analyzer, which samples a small volume of blood and measures various properties of white blood cells to produce a differential count. The manual differential, in which white blood cells are counted on a stained microscope slide, is now performed to investigate abnormal results from the automated differential, or upon request by the healthcare provider.
Sources: en.wikipedia.org
Some methods of creating a trophy mount do not involve preserving the actual body of the animal. Instead, detailed photos and measurements are taken of the animal so a taxidermist can create an exact replica in resin or fiberglass that can be displayed in place of the real animal. No animals are killed in the creation of this type of trophy mount. One situation where this is practiced is in the world of sport fishing where catch and release is becoming increasingly prevalent. Reproduction mounts are commonly created for (among others) trout, bass, and large saltwater species such as the swordfish and blue marlin. Another situation where reproduction trophies are created is when endangered species are involved. Endangered and protected species, such as the rhinoceros, are hunted with rifles loaded with tranquilizer darts rather than real bullets. While the animal is unconscious, the hunter poses for photos with the animal while it is measured for the purpose of creating a replica, or to establish what size of prefabricated fiberglass trophy head can be purchased to most closely approximate the actual animal. The darted animal is not harmed. The hunter then displays the fiberglass head on the wall in lieu of the real animal's head to commemorate the experience of the hunt.
Compounding this fact was that PLAN insurgents also identified themselves as refugees without making any distinction between their civilian or military background, and the UN had explicitly invited refugees to return home. Indeed, PLAN did not possess many regular standing units and by the late 1980s many of its personnel followed cyclical patterns of fighting as insurgents before returning to refugee camps as civilians. On 31 March 1989, Pik Botha complained to the JMMC that PLAN troops had advanced south of the 16th parallel and were massing less than eight kilometres from the border. He promptly intercepted UN Special Representative Martti Ahtisaari and UNTAG commander Dewan Prem Chand that evening and gave them the same information. On the morning of 1 April, the first PLAN cadres crossed into Ovamboland, unhindered by UNTAG, which had failed to monitor their activity in Angola due to the delays in its deployment. Ahtisaari immediately contacted SWAPO, ordering it to rein in PLAN, to little avail. The South African foreign ministry also contacted the Secretary-General, who in turn relayed the same message to SWAPO officials in New York. At the end of the day, with no signs of the PLAN advance abating, Ahtisaari lifted all restrictions confining the SADF to its bases. Local police mobilised and fought off the invaders in a delaying action until regular SADF forces were able to deploy with six battalions.
nucleotide Also nucleoside monophosphate (NMP). An organic molecule that serves as the fundamental monomer or subunit of nucleic acid polymers, including RNA and DNA. Each nucleotide is composed of three connected functional groups: a nitrogenous base, a five-carbon sugar (either ribose or deoxyribose), and a single phosphate group. Though technically distinct, the term "nucleotide" is often used interchangeably with nitrogenous base, nucleobase, and base pair when referring to the sequences that make up nucleic acids. Compare nucleoside.
=== Mercuration of aromatic rings === Electron-rich arenes, such as phenol, undergo mercuration upon treatment with Hg(O2CCH3)2. The one acetate group that remains on the mercury atom can be displaced by chloride:
Sources: en.wikipedia.org
In the United States, a medical laboratory scientist (MLS), medical technologist (MT), or a clinical laboratory scientist (CLS) typically earns a bachelor's degree in medical laboratory science, clinical laboratory science, or medical technology. Other routes include attaining a degree in biomedical science or in a life / biological science (biology, biochemistry, microbiology, etc.). Both routes typically requires the MLS/MT/CLS to obtain certification from a national certifying board (AAB, AMT, or ASCP) as most laboratories exceed the federal minimum requirements established by the Clinical Laboratory Improvement Amendments (CLIA). Common comprehensive medical laboratory scientist degree programs are set up in a few different ways.
== Chemistry == Etifoxine is a nonbenzodiazepine—that is, it is similarly a GABAA receptor positive allosteric modulator but its chemical structure is distinct from that of benzodiazepines. Instead, it is a benzoxazine derivative.
== Legality == In the United States, a letter from Terrence L. Boos, Ph.D., Chief Drug & Chemical Evaluation Section Diversion Control Division at the DEA shows they consider nor-BNI a Schedule II substance as a derivative of noroxymorphone due to its broad definition in the CSA covering "derivatives". However, no court cases are known to exist for its prosecution and it is possible this could be challenged in court.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.